title: Homocysteine levels and glucose metabolism in non-obese, non-diabetic chronic schizophrenia.
abstract: We studied a sample of schizophrenia out-patients to test the hypotheses that serum homocysteine concentrations would correlate positively with measures of glucose metabolism.
  
  
  
  Subjects underwent a nutritional assessment and fasting plasma, serum insulin and homocysteine tests.
  
  
  
  Males had a significantly higher homocysteine levels than females (7.69 +/- 1.42 microM vs. 6.63 +/- 1.40 microM; P = 0.02). Comparing subjects with normal fasting glucose (NFG) (glucose < 100 mg/dl) and impaired fasting glucose (IFG) (> or = 100 mg/dl) subjects with IFG (mean 8.2 +/- 1.5 microM) had significantly higher homocysteine levels than those with NFG (mean 7.2 +/- 1.4 microM, P = 0.03). IFG was also associated with greater mean values for a Homeostatic Model Assessment-Insulin Resistance (HOMA-IR) (P = 0.002) and diastolic blood pressure (P = 0.045).
  
  
  
  The group with IFG had higher fasting serum homocysteine concentrations than those with NFG which supports a connection to an important cardiovascular risk factor.
authors.affiliation: Schizophrenia Program, Massachusetts General Hospital, Boston, MA, USA. dchenderson@partners.org
authors.forename: D C
authors.initials: DC
authors.lastname: Henderson
authors.forename: P M
authors.initials: PM
authors.lastname: Copeland
authors.forename: D D
authors.initials: DD
authors.lastname: Nguyen
authors.forename: C P
authors.initials: CP
authors.lastname: Borba
authors.forename: C
authors.initials: C
authors.lastname: Cather
authors.forename: A E
authors.initials: AE
authors.lastname: Evins
authors.forename: O
authors.initials: O
authors.lastname: Freudenreich
authors.forename: L
authors.initials: L
authors.lastname: Baer
authors.forename: D C
authors.initials: DC
authors.lastname: Goff
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use; D001569:Benzodiazepines / Q000627:therapeutic use; D001786:Blood Glucose / Q000378:metabolism*; D001794:Blood Pressure / Q000502:physiology; D002908:Chronic Disease; D003024:Clozapine / Q000627:therapeutic use; D003155:Community Mental Health Centers; D005260:Female; D005492:Folic Acid / Q000097:blood; D006706:Homeostasis / Q000502:physiology; D006710:Homocysteine / Q000097:blood*; D006801:Humans; D007328:Insulin / Q000097:blood; D007333:Insulin Resistance / Q000502:physiology; D008297:Male; D008875:Middle Aged; D015596:Nutrition Assessment; D000077152:Olanzapine; D011236:Prediabetic State / Q000097:blood / Q000175:diagnosis; D011618:Psychotic Disorders / Q000097:blood* / Q000188:drug therapy; D012016:Reference Values; D012307:Risk Factors; D018967:Risperidone / Q000627:therapeutic use; D012559:Schizophrenia / Q000097:blood* / Q000188:drug therapy; D012737:Sex Factors; D013223:Statistics as Topic; D049629:Waist-Hip Ratio
chemical_list: D014150:Antipsychotic Agents; D001786:Blood Glucose; D007328:Insulin; D006710:Homocysteine; D001569:Benzodiazepines; D005492:Folic Acid; D003024:Clozapine; D018967:Risperidone; D000077152:Olanzapine